tiprankstipranks
Trending News
More News >
BioCorRx Inc (BICX)
OTHER OTC:BICX
US Market

BioCorRx (BICX) AI Stock Analysis

Compare
5 Followers

Top Page

BI

BioCorRx

(OTC:BICX)

Rating:28Underperform
Price Target:
BioCorRx's overall stock score is significantly impacted by its weak financial performance, characterized by declining revenues, high leverage, and negative cash flows. Technical analysis provides a slight positive note with signs of potential upward momentum, but the valuation remains a major concern due to negative profitability metrics. The absence of earnings call data and corporate events further emphasizes the need for a strategic turnaround.

BioCorRx (BICX) vs. SPDR S&P 500 ETF (SPY)

BioCorRx Business Overview & Revenue Model

Company DescriptionBioCorRx Inc. is a healthcare solutions company operating primarily in the substance use disorder treatment sector. The company offers a range of products and services aimed at combating addiction, including a proprietary implantable naltrexone pellet for alcohol and opioid use disorders. Their offerings are designed to support individuals in their recovery journey through a combination of medical intervention and behavioral therapy programs.
How the Company Makes MoneyBioCorRx Inc. generates revenue through the sale of its addiction treatment products, particularly its naltrexone implant, which is distributed to healthcare providers and clinics specializing in addiction treatment. The company also makes money by offering a comprehensive recovery program that includes counseling and support services, which can be sold directly to treatment centers or licensed as a package. Additionally, BioCorRx may engage in partnerships with medical facilities and practitioners to expand the reach of its programs and products, contributing to its revenue streams.

BioCorRx Financial Statement Overview

Summary
BioCorRx is facing significant financial challenges, with declining revenues, consistent losses, high leverage, and negative cash flows. The company's financial health is weak, indicating an urgent need for a strategic turnaround to improve its financial position.
Income Statement
20
Very Negative
BioCorRx's revenue has declined significantly from 2020 to 2024, with a noticeable drop in 2024. Both EBIT and EBITDA margins are deeply negative, indicating operational inefficiencies and financial distress. Net profit margins are also negative, showing consistent losses over the years.
Balance Sheet
15
Very Negative
The company has a negative stockholders' equity, which is concerning. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is negative, indicating liabilities exceed assets significantly. This highlights a high leverage risk and financial instability.
Cash Flow
25
Negative
Operating cash flow is negative, showing the company is not generating enough cash from operations. Free cash flow is also negative, although there was an improvement in financing cash flow. The free cash flow to net income ratio is unfavorable, pointing to poor cash conversion from net income.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue201.28K7.67K89.16K213.84K48.27K122.62K
Gross Profit166.28K6.00K53.17K198.56K42.39K26.67K
EBITDA-3.63M-3.59M-2.68M-3.15M-4.48M-2.83M
Net Income-4.71M-5.11M-3.77M-4.37M-5.80M-4.01M
Balance Sheet
Total Assets6.80M385.94K388.89K766.59K819.98K1.83M
Cash, Cash Equivalents and Short-Term Investments24.14K88.03K65.22K68.61K85.84K592.05K
Total Debt2.74M2.81M1.81M1.68M1.65M955.59K
Total Liabilities18.60M12.74M10.34M8.97M7.78M6.04M
Stockholders Equity-11.80M-12.12M-9.82M-8.08M-6.84M-4.09M
Cash Flow
Free Cash Flow-1.45M-1.10M-1.85M-2.04M-3.59M-2.16M
Operating Cash Flow-1.45M-1.10M-1.85M-2.04M-3.54M-2.15M
Investing Cash Flow0.000.000.000.00-50.00K-9.23K
Financing Cash Flow1.37M1.12M1.85M2.02M3.08M107.30K

BioCorRx Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.36
Price Trends
50DMA
0.33
Positive
100DMA
0.35
Positive
200DMA
0.36
Negative
Market Momentum
MACD
<0.01
Negative
RSI
53.74
Neutral
STOCH
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BICX, the sentiment is Positive. The current price of 0.36 is above the 20-day moving average (MA) of 0.36, above the 50-day MA of 0.33, and below the 200-day MA of 0.36, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.74 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BICX.

BioCorRx Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.45B0.27-61.87%2.30%16.62%1.04%
31
Underperform
$7.32M-3028.18%19.58%
29
Underperform
$4.30M-91.32%48.81%
28
Underperform
$6.12M41.50%-91.40%-8.98%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BICX
BioCorRx
0.36
-0.11
-23.40%
KZIA
Kazia Therapeutics
6.82
-2.78
-28.96%
GLTO
Galecto
3.32
-9.32
-73.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025